Expect a Limited Role for the New HIV Drug, Juluca

Juluca (jah-LOO-kah, dolutegravir/rilpivirine) will be the first two-drug combo that's a COMPLETE treatment regimen for HIV.

Most patients use THREE meds to treat HIV...often two nucleoSIDE/ nucleoTIDE reverse transcriptase inhibitors (NRTIs) PLUS another antiretroviral from a different class.

Juluca doesn't have an NRTI. It combines the integrase inhibitor, dolutegravir (Tivicay), with the NON-nucleoside reverse transcriptase inhibitor, rilpivirine (Edurant). It's a single tablet taken once daily.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote